Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Use of sacubitril-valsartan in heart failure with reduced ejection fraction: Real world experience
Session:
Posters 5 - Écran 6 - Insuficiência Cardíaca
Speaker:
Fernanda Costa Ferreira
Congress:
CPC 2019
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.4 Chronic Heart Failure – Treatment
Session Type:
Posters
FP Number:
---
Authors:
Fernanda Costa Ferreira; Sergio Manuel Ferreira Cristina; Ana Filipa Raposo; Elizabeth Maciel de Albuquerque; Inês Nabais; Carla Matias; Marta Afonso Nogueira; Rafael Vasconcellos; Gonçalo Miranda Proença
Abstract
<p>Introduction: Sacubitril/Valsartan (Sac/Val) significantly reduces hospitalizations and mortality of heart failure patients (pts) with reduced ejection fraction (HFrEF). Considering that real world evidence are still scarce, it’s important to report our experience regarding safety and efficacy of this drug, after approximately one year of its introduction in Portugal. Methods: From November 2017 to November 2018, 73 patients (pts) were switched from Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker (ACEI-ARB) to Sac/Val. Data of 58 pts (79% men), with ischemic aetiology (60%) and left ventricular ejection fraction (LVEF) of 29.5<u>+</u>6.8% were retrospectively analyzed. Mean age was 70,5<u>+</u>12.5 years old. At the start of therapy with Sac/Val, 57% of pts were in NYHA class II, 33% in NYHA class III and 5% in NYHA class IV. Mean NTproBNP before the switch of therapy was 5043 pg/ml. Concerning ESC guideline Class I Recommendation for HF therapy, 93% of pts were using betablockers, 91% ACEI/ARB, 60% mineralocorticoid/aldosterone receptor antagonist, 74% loop diuretics, and 17% ivabradine. Ten percent had CRT and 22% ICD. In 25 pts (43,1%), initial Sac/Val dose of 24/25mg bid was not augmented. In 41,4% of pts was possible to achieve an intermediary dose of 49/51mg bid and in 15,5% the maximum dose was achieved. Clinical efficacy (HF hospitalization, death, NYHA class improvement), safety (arterial pressure, serum potassium, creatinine), NTproBNP and echocardiographic (LVEF) parameters were analyzed. Results: There was improvement of NYHA class, with no pts remaining in NYHA class IV. One pt had worsened NYHA class from II to III. Among remaining pts, 29 (50%) improved NYHA class. There were 2 unplanned hospitalizations for HF after switch of therapy, and there was 1 death of refractory HF. About safety concerns, there were no major event associated with therapy switch: mean arterial pressure was 126,9<u>+</u>17,5 mmHg, serum potassium (4,6<u>+</u>0,4 mmol/L) and renal function (CR 1,2+0,4mg/dl) remained stable. There wasn´t any report of angioedema. LVEF after switch therapy improved from 29,5<u>+</u>6,8 to 36,2<u>+</u>8,9%. Conclusion: Therapy with Sac/Val, when associated to other ESC guideline Class I Recommendation HF therapies, was effective in improving NYHA class and reducing hospitalizations being associated to low risk of complications.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site